Home High Flow Oxygen to Reduce Acute Exacerbation of COPD (HIFAE)
Primary Purpose
Chronic Obstructive Pulmonary Disease
Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
High Flow Oxygen Therapy
Long-term oxygen therapy
Sponsored by
About this trial
This is an interventional other trial for Chronic Obstructive Pulmonary Disease
Eligibility Criteria
Inclusion Criteria:
- Patient with a diagnosis of COPD defined by GOLD guidelines
- Admitted in hospital for AECOPD
With severe respiratory impairment defined by one of the following criteria (long-term oxygen therapy (LTOT) criteria):
- Previously established on long-term oxygen therapy according to the following criteria: PaO2 < 7.3kPa or <8kPa with polycythemia, pulmonary hypertension or right heart failure on room air in stable condition Or
- PaO2 < 7.3kPa or <8kPa with polycythemia, pulmonary hypertension or right heart failure on room air after clinical stabilization during the index admission
- Patients affiliated or, beneficiary of a social security cover
- Patient who has read and understood the information letter and signed the consent form
- For woman of childbearing potential, use of an effective contraception (oestro-progestatives or intra-uterine device or tubal ligation) since at least 1 month and an blood pregnancy test by β-HCG negative at the screening visit, during the duration of the study
- For menopausal woman: confirmatory diagnosis (amenorrhea not medically induced for at least 12 months before the inclusion visit)
Exclusion Criteria:
- Age <18 or > 85 years
- Patient treated with chronic NIV with ongoing treatment
- Patients diagnosed with obstructive sleep apnea (OSA) treated with CPAP. Diagnosis of OSA will be over-ruled in patient that had a previous overnight polygraphy. For patients who never had an overnight polygraphy, screening for OSA will be made using the STOP-BANG questionnaire. If the results of the STOP-BANG questionnaire (Appendix 1) is >3, an Apnea-link recording will be performed. If AHI>30/h, patient will be excluded.
- BMI > 35 kg/m2
- Patient admitted for an acute COVID-19 infection
Hypercapnic respiratory failure justifying NIV defined as
- An Arterial Blood Gas (ABG) PaCO2 > 7 kPa in stable condition within 6 months
- Patients with ABG PaCO2 > 7 kPa at hospital discharge and that remained hypercapnic between 2- and 4-weeks following discharge
- Pregnancy (blood pregnancy test positive) or lactation ongoing
- Significant psychiatric disorder or dementia that would prevent adherence to study protocol
- Tobacco use < 10 pack-year
- Expected survival < 12 months due to any situation other than COPD disease
- Refusal of high-flow oxygen therapy
- Person deprived of liberty by administrative or judicial decision or placed under judicial protection (guardianship or supervision)
- Patients already involved in a research protocol that would impact with the outcome measured in the current protocol
Sites / Locations
- UHRouenRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Other
Arm Label
High Flow Oxygen Therapy
Long-Term Oxygen Therapy
Arm Description
Control arm
Outcomes
Primary Outcome Measures
time to first hospital admission for Acute Exacerbation of Chronic Obstructive Pulmonary Disease
time to death
Secondary Outcome Measures
Change from Baseline in Health-related Quality of Life
Health-related quality of life is evaluated using Saint-Georges Respiratory score
Change from Baseline in Health-related Quality of Life
Health-related quality of life is evaluated using Saint-Georges Respiratory score
Change from Baseline in Health-related Quality of Life
Health-related quality of life is evaluated using Saint-Georges Respiratory score
Change from Baseline in Health-related Quality of Life
Health-related quality of life is evaluated using EuroQol-5D-5L score
Change from Baseline in Health-related Quality of Life
Health-related quality of life is evaluated using EuroQol-5D-5L score
Change from Baseline in Health-related Quality of Life
Health-related quality of life is evaluated using EuroQol-5D-5L score
Change from Baseline in Health-related Quality of Life
Health-related quality of life is evaluated using Hospital anxiety and depression scale
Change from Baseline in Health-related Quality of Life
Health-related quality of life is evaluated using Hospital anxiety and depression scale
Change from Baseline in Health-related Quality of Life
Health-related quality of life is evaluated using Hospital anxiety and depression scale
Change from Baseline in Health-related Quality of Life
Health-related quality of life is evaluated using Leicester Cough Questionnaire score
Change from Baseline in Health-related Quality of Life
Health-related quality of life is evaluated using Leicester Cough Questionnaire score
Change from Baseline in Health-related Quality of Life
Health-related quality of life is evaluated using Leicester Cough Questionnaire score
Change from Baseline in Health-related Quality of Life
Health-related quality of life is evaluated using Chronic Obstructive Pulmonary Disease Assessments Test score
Change from Baseline in Health-related Quality of Life
Health-related quality of life is evaluated using Chronic Obstructive Pulmonary Disease Assessments Test score
Change from Baseline in Health-related Quality of Life
Health-related quality of life is evaluated using Chronic Obstructive Pulmonary Disease Assessments Test score
Change from Baseline in Health-related Quality of Life
Health-related quality of life is evaluated using Pittsburgh sleep quality index score
Change from Baseline in Health-related Quality of Life
Health-related quality of life is evaluated using Pittsburgh sleep quality index score
Change from Baseline in Health-related Quality of Life
Health-related quality of life is evaluated using Pittsburgh sleep quality index score
Number of Adverse events
Imputability of Adverse events is evaluated by investigator
Number of Adverse events
Imputability of Adverse events is evaluated by investigator
Number of Adverse events
Imputability of Adverse events is evaluated by investigator
Full Information
NCT ID
NCT05196698
First Posted
November 30, 2021
Last Updated
May 23, 2023
Sponsor
University Hospital, Rouen
1. Study Identification
Unique Protocol Identification Number
NCT05196698
Brief Title
Home High Flow Oxygen to Reduce Acute Exacerbation of COPD
Acronym
HIFAE
Official Title
Home High Flow Oxygen to Reduce Acute Exacerbation of COPD
Study Type
Interventional
2. Study Status
Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
August 26, 2022 (Actual)
Primary Completion Date
August 26, 2026 (Anticipated)
Study Completion Date
August 26, 2026 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Rouen
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The objective of the study is to evaluate the efficacy of home High Flow Oxygen for the reduction of severe exacerbation following admission for a severe exacerbation of COPD or death against standard oxygen therapy.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Obstructive Pulmonary Disease
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
406 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
High Flow Oxygen Therapy
Arm Type
Experimental
Arm Title
Long-Term Oxygen Therapy
Arm Type
Other
Arm Description
Control arm
Intervention Type
Other
Intervention Name(s)
High Flow Oxygen Therapy
Intervention Description
HFOT will be delivered validated medical devices and established as follow:
Patient will be acclimatized to HFOT which will aim to achieve a flow of air of 30L/min at a temperature of 34°C using dedicated nasal canula.
Once patient acclimatized, oxygen will be entrained in the HFOT device at a flow that will aim to achieve a saturation > 90%. An arterial blood gas will be performed with such oxygen delivery, flowrate and temperature to ensure a PaO2 ≥ 8kPa
Intervention Type
Other
Intervention Name(s)
Long-term oxygen therapy
Intervention Description
LTOT delivery will be performed according to French guidelines
Primary Outcome Measure Information:
Title
time to first hospital admission for Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Time Frame
12 months
Title
time to death
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Change from Baseline in Health-related Quality of Life
Description
Health-related quality of life is evaluated using Saint-Georges Respiratory score
Time Frame
3 months
Title
Change from Baseline in Health-related Quality of Life
Description
Health-related quality of life is evaluated using Saint-Georges Respiratory score
Time Frame
6 months
Title
Change from Baseline in Health-related Quality of Life
Description
Health-related quality of life is evaluated using Saint-Georges Respiratory score
Time Frame
12 months
Title
Change from Baseline in Health-related Quality of Life
Description
Health-related quality of life is evaluated using EuroQol-5D-5L score
Time Frame
3 months
Title
Change from Baseline in Health-related Quality of Life
Description
Health-related quality of life is evaluated using EuroQol-5D-5L score
Time Frame
6 months
Title
Change from Baseline in Health-related Quality of Life
Description
Health-related quality of life is evaluated using EuroQol-5D-5L score
Time Frame
12 months
Title
Change from Baseline in Health-related Quality of Life
Description
Health-related quality of life is evaluated using Hospital anxiety and depression scale
Time Frame
3 months
Title
Change from Baseline in Health-related Quality of Life
Description
Health-related quality of life is evaluated using Hospital anxiety and depression scale
Time Frame
6 months
Title
Change from Baseline in Health-related Quality of Life
Description
Health-related quality of life is evaluated using Hospital anxiety and depression scale
Time Frame
12 months
Title
Change from Baseline in Health-related Quality of Life
Description
Health-related quality of life is evaluated using Leicester Cough Questionnaire score
Time Frame
3 months
Title
Change from Baseline in Health-related Quality of Life
Description
Health-related quality of life is evaluated using Leicester Cough Questionnaire score
Time Frame
6 months
Title
Change from Baseline in Health-related Quality of Life
Description
Health-related quality of life is evaluated using Leicester Cough Questionnaire score
Time Frame
12 months
Title
Change from Baseline in Health-related Quality of Life
Description
Health-related quality of life is evaluated using Chronic Obstructive Pulmonary Disease Assessments Test score
Time Frame
3 months
Title
Change from Baseline in Health-related Quality of Life
Description
Health-related quality of life is evaluated using Chronic Obstructive Pulmonary Disease Assessments Test score
Time Frame
6 months
Title
Change from Baseline in Health-related Quality of Life
Description
Health-related quality of life is evaluated using Chronic Obstructive Pulmonary Disease Assessments Test score
Time Frame
12 months
Title
Change from Baseline in Health-related Quality of Life
Description
Health-related quality of life is evaluated using Pittsburgh sleep quality index score
Time Frame
3 months
Title
Change from Baseline in Health-related Quality of Life
Description
Health-related quality of life is evaluated using Pittsburgh sleep quality index score
Time Frame
6 months
Title
Change from Baseline in Health-related Quality of Life
Description
Health-related quality of life is evaluated using Pittsburgh sleep quality index score
Time Frame
12 months
Title
Number of Adverse events
Description
Imputability of Adverse events is evaluated by investigator
Time Frame
3 months
Title
Number of Adverse events
Description
Imputability of Adverse events is evaluated by investigator
Time Frame
6 months
Title
Number of Adverse events
Description
Imputability of Adverse events is evaluated by investigator
Time Frame
12 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patient with a diagnosis of COPD defined by GOLD guidelines
Admitted in hospital for AECOPD
With severe respiratory impairment defined by one of the following criteria (long-term oxygen therapy (LTOT) criteria):
Previously established on long-term oxygen therapy according to the following criteria: PaO2 < 7.3kPa or <8kPa with polycythemia, pulmonary hypertension or right heart failure on room air in stable condition Or
PaO2 < 7.3kPa or <8kPa with polycythemia, pulmonary hypertension or right heart failure on room air after clinical stabilization during the index admission
Patients affiliated or, beneficiary of a social security cover
Patient who has read and understood the information letter and signed the consent form
For woman of childbearing potential, use of an effective contraception (oestro-progestatives or intra-uterine device or tubal ligation) since at least 1 month and an blood pregnancy test by β-HCG negative at the screening visit, during the duration of the study
For menopausal woman: confirmatory diagnosis (amenorrhea not medically induced for at least 12 months before the inclusion visit)
Exclusion Criteria:
Age <18 or > 85 years
Patient treated with chronic NIV with ongoing treatment
Patients diagnosed with obstructive sleep apnea (OSA) treated with CPAP. Diagnosis of OSA will be over-ruled in patient that had a previous overnight polygraphy. For patients who never had an overnight polygraphy, screening for OSA will be made using the STOP-BANG questionnaire. If the results of the STOP-BANG questionnaire (Appendix 1) is >3, an Apnea-link recording will be performed. If AHI>30/h, patient will be excluded.
BMI > 35 kg/m2
Patient admitted for an acute COVID-19 infection
Hypercapnic respiratory failure justifying NIV defined as
An Arterial Blood Gas (ABG) PaCO2 > 7 kPa in stable condition within 6 months
Patients with ABG PaCO2 > 7 kPa at hospital discharge and that remained hypercapnic between 2- and 4-weeks following discharge
Pregnancy (blood pregnancy test positive) or lactation ongoing
Significant psychiatric disorder or dementia that would prevent adherence to study protocol
Tobacco use < 10 pack-year
Expected survival < 12 months due to any situation other than COPD disease
Refusal of high-flow oxygen therapy
Person deprived of liberty by administrative or judicial decision or placed under judicial protection (guardianship or supervision)
Patients already involved in a research protocol that would impact with the outcome measured in the current protocol
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Antoine CUVELIER, Pr
Phone
+33232889059
Email
antoine.cuvelier@chu-rouen.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Armelle GUIDOTTI
Phone
+33232888265
Email
armelle.guidotti@chu-rouen.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Antoine CUVELIER, Pr
Organizational Affiliation
Rouen University Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Maxime PATOUT, Dr
Organizational Affiliation
AP-HP La Pitié Salpétrière
Official's Role
Principal Investigator
Facility Information:
Facility Name
UHRouen
City
Rouen
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Antoine CUVELIER, Pr
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Home High Flow Oxygen to Reduce Acute Exacerbation of COPD
We'll reach out to this number within 24 hrs